China should not only API client state

Although the Indian pharmaceutical industry like China has not yet developed a significant international influence of the "blockbuster drug", but India's exports in the generic drug formulations has been ranked first in the third world countries. U.S., EU and Russia have become the three Indian pharmaceutical export market in Southeast Asia / South Asia and Middle East / Arab region is India's pharmaceutical exports to traditional markets. India, exports to Asia has become the generic drug formulations "leader."China's pharmaceutical raw materials industry is worth pondering is that the success of India's export of agents, a considerable part of China should be attributed to a large number of Indian exports of bulk drugs. It is understood that in recent years, India has become China's largest buyers of bulk drugs. Bulk purchase of Chinese-Indian penicillin G potassium salt ,7-ACA (semi-synthetic cephalosporin key raw materials), erythromycin thiocyanate (synthetic macrolide antibiotic drug intermediates bulk drugs major), paracetamol, ibuprofen, aspirin and dipyrone and other bulk products, and in its preparation or other domestic processing into high value-added products for export to other countries, to obtain high profits. If Chinese companies do not let this situation continue to make efforts, it really will become India's "API vassal state" (Indian media language), can only take "a large number of exports to countries such as India, bulk drugs," the road.According to the latest Associated Press reported in 2007 - 2008 fiscal year, total exports of the Indian pharmaceutical industry $ 7.2 billion drug substances and drug products. India's exports last year, the total amount of bulk drugs and formulations is estimated to have close to or over $ 10 billion. Expected the next few years the Indian pharmaceutical exports growth rate will reach 18%. Although the Indian pharmaceutical exports in the total amount can not be compared with China still (according to statistics, China exported $ 18 billion last year, a total of API products), Resveratrol but exports of formulations and bulk drugs in the margins, the Chinese enterprises are not as good as India. The most telling example is the Indian pharmaceutical companies use cheap imports from China, ibuprofen, ceftriaxone, and ampicillin and other raw materials processed into drug formulations, a large number sold in Europe, America and Russia, the Middle East market to earn profits. The Chinese API manufacturers as the hand is not cGMP, COS certificate and other international markets permit, only watched the Indian companies to take China's rich API.It is understood that in order to further expand the international pharmaceutical drugs in India's influence on the market, the Indian government has been in the country's largest city, Mumbai, held for the 3rd International exhibition of chemical medicine raw material medicine (India CPHI). According to foreign media reports, was held in Mumbai in December last year, the third at CPHI India, a total of more than 600 manufacturers in 80 countries participating. Indian Commerce and Industry officials announced at this show, the Indian pharmaceutical industrial output value in 2015 is expected to scale than it is now four times to $ 25 billion - this will be an amazing leap forward.India's exports of finished products draw on the experience, the Chinese pharmaceutical companies should draw profound lessons, because the export of bulk drugs in most cases can only get a small profit. To make matters worse, Chia seed the production of bulk drugs have greatly exceeded the preparation of environmental pollution industry. Back in the late 1980s, China experienced in the industry that many people said, "made in China, foreigners bought a cheap raw material medicine, the pollution to remain in China." Adjust the industrial structure in the country, promote low-carbon economy today, the pharmaceutical industry should be practical action to "API client country" say no. But to completely change the current situation, China's pharmaceutical enterprises should learn from the successful experience of the Indian pharmaceutical industry, for China to allow more preparation to go abroad, to enter the international mainstream market. This will not only be able to obtain higher economic returns, but also reduce the production of bulk drugs caused by environmental pollution. Source:http://www.cospcn.com